NCT04905914: Study Of ATRN-119 In Patients With Advanced Solid Tumors

NCT04905914
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known unstable CNS metastases – see trial for details; Patients with prior radiotherapy at the target lesion unless there is evidence of disease progression
https://ClinicalTrials.gov/show/NCT04905914

Comments are closed.

Up ↑